Clinical

Our xTAG® and MultiCode™-RTx Technologies serve a wide range of clinical applications, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.
 
Read More

Research & Applied Markets

Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.
 
Read More

Become a Partner

Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology. Click here to start the conversation now.
 
Learn More

Luminex® Blog

METHODS Special Issue: Multiplex Assays Enable Simultaneous Measurement of RNA and Proteins

A more comprehensive view sheds light on the biological response to muscle injury

Scientists at the University of North Texas have established a novel method for measuring a broad range of RNA and protein biomarkers. In their study, they employed bead-based multiplex detection to assess the effects of skeletal muscle injury over time, but the same concept could be useful for many clinical applications.

Continue Reading >

VERIGENE® Respiratory Pathogens Flex Test

 
Video Thumbnail
VERIGENE® Respiratory Pathogens Flex Test (RP Flex)
  Clinical Our xTAG® and MultiCode™-RTx Technologies serve a wide range of clinical applications, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.  Read More Research & Applied Markets Our xMAP® Technology and its flexible, open-a

 

The VERIGENE® Respiratory Pathogens Flex Test (RP Flex) is an automated, multiplexed, flexible nucleic acid test for the identification of the viruses and bacteria that most commonly cause respiratory infections.

Watch more videos >

Luminex on Twitter


RT @CDCDirector: .@CDCgov does not recommend the use of facemasks or personal protective equipment (PPE) among well people in the general p…
h J R
By testing only patients with clinical symptoms of a 𝘊. 𝘥𝘪𝘧𝘧 infection, we may be missing many asymptomatic carrier… https://t.co/fmFHdme6ES
h J R
Welcome to Manchester, #BIOMUK20! We're excited to learn about the latest advances in #biomarkers + to share our ow… https://t.co/BR0Wts4Bbh
h J R

Latest News

18th February
Luminex Corporation Declares First Quarter Cash Dividend

13th February
Luminex Corporation to Participate At Upcoming Healthcare Investor Conferences in March 2020

10th February
Luminex Corporation Reports Fourth Quarter and Full-Year 2019 Results

Events

Swiss Flow Cytometry
5-7 February
Lausanne, Switzerland


Biomarkers
18-20 February
Manchester, UK